Related references
Note: Only part of the references are listed.Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers
Linda Villard et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide
Ebrahim S. Delpassand et al.
THERANOSTICS (2012)
Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Dik J. Kwekkeboom et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2011)
Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy
Samer Ezziddin et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
Samer Ezziddin et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors
Martijn van Essen et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
Dik J. Kwekkeboom et al.
SEMINARS IN NUCLEAR MEDICINE (2010)
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE:: the role of associated risk factors
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer:: A phase II clinical trial
Fabienne Iten et al.
CLINICAL CANCER RESEARCH (2007)
Long-term toxicity of [177Lu-DOTA0,Tyr3]octreotate in rats
Edgar J. Rolleman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
From outside to inside?: Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo 99mTc-DMSA-SPECT and molecular imaging
Flavio Forrer et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2007)
Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours
Martijn Van Essen et al.
ACTA ONCOLOGICA (2007)
Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors
Andrea Frilling et al.
SURGERY (2006)
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced
R Valkema et al.
SEMINARS IN NUCLEAR MEDICINE (2006)
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors
DJ Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
DJ Kwekkeboom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion:: a phase I study
L Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide:: The Rotterdam experience
R Valkema et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies
TM Behr et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies
LB Anthony et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide:: The experience of the European Institute of Oncology Group
M Chinol et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
End-stage renal disease after treatment with 90Y-DOTATOC
M Cybulla et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours:: A clinical phase II study
C Waldherr et al.
ANNALS OF ONCOLOGY (2001)
A new cause of renal thrombotic microangiopathy: Yttrium 90-DOTATOC internal radiotherapy
S Moll et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2001)
Share Paper
